Generic lorazepam oral solution is supplied in a 30 mL multi-dose bottle requiring protection from light and refrigeration, with a beyond use date of 90 days once the bottle is opened. The repackaging of 1 mL doses of lorazepam oral solution into oral syringes allows for facilitated dispensing, yet no available data supports repackaging and storing lorazepam oral solution in syringes. The validation and application of a stability-indicating high-performance liquid chromatography with ultraviolet detection (HPLC-UV) method for the quantification of lorazepam allowed for the determination of the stability of lorazepam oral solution when stored in oral syringes. A stability-indicating HPLC-UV method was developed for the quantification of lorazepam in oral solution. The method was validated using guidance from USP < 1225 >. For the stability investigation, 2 mg/mL lorazepam oral solution was aliquoted into clear plastic oral syringes in 1 mLmilliliter doses from 2 multi-dose stock bottles and randomly allocated for storage in room temperature or refrigerated environment. Baseline lorazepam concentrations were measured on the day the study was initiated and designated as 100% initial concentration samples. Subsequent samples were analyzed in triplicate at time points of 24, 48, and 96 hours and 7, 10, 14, 21, 30, and 60 days. The calibration curves on three non-consecutive days met the linearity criteria of > 0.99. Inter- day and intra-day precision and accuracy (percent relative standard deviation and percent error) were ≤2% over three days. During the stability investigation, percent initial concentration of lorazepam from room and refrigerated syringes remained above 90% for the duration of the study. The stability-indicating HPLC-UV method was successfully applied to the investigation of lorazepam oral solution stability when stored in syringes at room and refrigerated temperatures. The emergent need for use of lorazepam concentrate for inpatients and the restrictions of how the medication is supplied necessitated a need for the evaluation of repackaging into unit dose syringes for immediate availability from automated dispensing cabinets. Lorazepam oral solution stored in clear plastic syringes maintained greater than 90% initial concentration at both room and refrigerated temperatures for 60 days.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11195844PMC
http://dx.doi.org/10.1177/00185787241232112DOI Listing

Publication Analysis

Top Keywords

lorazepam oral
36
oral solution
36
oral syringes
16
room refrigerated
16
lorazepam
13
oral
13
hplc-uv method
12
initial concentration
12
solution
9
syringes
9

Similar Publications

Purpose: To evaluate the efficacy and safety of intranasal dexmedetomidine (Dex), oral lorazepam, and a placebo in managing preoperative anxiety-related insomnia.

Patients And Methods: A total of 90 patients exhibiting symptoms of preoperative anxiety and insomnia were randomly assigned to three groups: Dex (receiving 2.5 µg/kg Dex intranasally and starch tablets orally), lorazepam (receiving saline intranasally and 2 mg lorazepam orally), and placebo (receiving saline intranasally and starch tablets orally).

View Article and Find Full Text PDF

Corticosteroid-induced psychosis is rare and less reported in children compared to adults. However, psychosis is considered a severe adverse effect of corticosteroids in pediatric nephrotic syndrome. Steroid-induced psychosis is dose-dependent and should be treated by tapering the dose of steroids and usually initiating an atypical antipsychotic.

View Article and Find Full Text PDF

Background In a previously published study about the effects of an inpatient geriatrics program on mortality among older patients with and without cognitive impairment, intravenous (IV) lorazepam was unexpectedly found to be one of the variables associated with mortality in the multivariate analysis. The purpose of this study was to further explore the association between IV lorazepam and mortality. Materials and Methods This was a secondary data analysis of a previously published retrospective study.

View Article and Find Full Text PDF

Mitigation of addictive effects induced by lorazepam through concurrent administration of SSRI: Interplay of serotonin and dopamine in caudate and nucleus accumbens.

Pak J Pharm Sci

September 2024

Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Karachi, Pakistan/Neuroscience Research Laboratory, Dr Panjwani Center for Molecular Medicine and Drug Research, ICCBS, University of Karachi, Karachi, Pakistan.

Article Synopsis
  • The study investigates how fluoxetine, an antidepressant, affects rats that have become dependent on lorazepam, a common anxiety and sedative medication.
  • It emphasizes the potential of fluoxetine to counteract lorazepam's addiction-related effects by enhancing serotonin levels, which may help regulate dopamine activity linked to addiction.
  • Various behaviors were tested in rats, including growth, food intake, and responses in stress-related tasks, to assess the influence of lorazepam and fluoxetine on addiction behaviors.
View Article and Find Full Text PDF

Introduction/aim: The study examines how chronic resveratrol administration affects behavioral and neurochemical changes caused by Lorazepam (LZP), a classical anti-anxiety medicine associated with neurodegenerative and neurological problems.

Method: Forty male rats were placed into four groups: a control group receiving 1% Tween 80, the LZP group receiving 2 mg/kg/day, the Resveratrol group receiving 50 mg/kg/day, and the LZP plus resveratrol group receiving the same doses of LZP and Resveratrol. Oral therapy was given daily for 6 weeks.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!